Financial updates
Pharming Group reports first quarter 2025 financial results and provides business update
Pharming Group N.V. presents its preliminary unaudited financial report for the three months ended March 31, 2025.
- First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024
- RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product’s unique position in the on-demand HAE market
- Joenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quarters
- Operating profit, adjusted to exclude the impact of non-recurring Abliva acquisition-related expenses, amounted to US$0.8 million compared to a US$16.3 million loss in the first quarter 2024
- Launched Joenja® (leniolisib) in England and Wales in April and preparing to file for U.S. FDA approval for pediatrics in the third quarter 2025
- Completed the acquisition of Abliva AB during the quarter and, in April, promptly started the second wave of recruitment for the pivotal FALCON clinical trial in mitochondrial DNA-driven primary mitochondrial diseases
- 2025 total revenue guidance raised to US$325 - US$340 million, up from prior US$315 - US$335 million
- Announces that Jeroen Wakkerman, Chief Financial Officer, will leave Pharming at the end of the month, to pursue other opportunities
- Pharming to host a conference call today at 13:30 CEST (7:30 am EDT) (view webcast)